Page 198 - 80 guidelines for the treatment of malaria_opt
P. 198

nd
              Guidelines for the treatment of malaria – 2  edition


            46.  Fryauff DJ et al. Chloroquine-resistant Plasmodium vivax in transmigration settlements
                 of West Kalimantan, Indonesia. American Journal of Tropical Medicine and Hygiene, 1998,
                 59:513–518.
            47.   Taylor WRJ et al. Chloroquine/doxycycline combination versus chloroquine alone and
                 doxycycline alone for the treatment of Plasmodium falciparum and Plasmodium vivax
                 malaria in northeastern Irian Jaya, Indonesia. American Journal of Tropical Medicine and
                 Hygiene, 2001, 64:223–228.
            48.  Fryauff DJ et al. The drug sensitivity and transmission dynamics of human malaria on
                 Nias Island, North Sumatra, Indonesia. Annals of Tropical Medicine and Parasitology, 2002,
                 96:447–462.
            49.   Maguire JD et al. Chloroquine-resistant Plasmodium malariae in south Sumatra, Indonesia.
                 Lancet, 2002, 360:58–60.
            50.  Sumawinata  IW  et  al.  Very  high  risk  of  therapeutic  failure  with  chloroquine  for
                 uncomplicated Plasmodium falciparum and P. vivax malaria in Indonesian Papua. American
                 Journal of Tropical Medicine and Hygiene, 2003, 68:416–420.
            51.   Schuurkamp GJ et al. Chloroquine-resistant Plasmodium vivax in Papua New Guinea.
                 Transactions of the Royal Society of Tropical Medicine and Hygiene, 1992, 86:121–122.
            52.  Myat-Phone-Kyaw et al. Emergence of chloroquine-resistant Plasmodium vivax in
                 Myanmar (Burma). Transactions of the Royal Society of Tropical Medicine and Hygiene,
                 1993, 87:687.
            53.   Marlar-Than et al. Development of resistance to chloroquine by Plasmodium vivax in
                 Myanmar. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1995,
                 89:307–308.
            54.  Dua VK, Kar PK, Sharma VP, Chloroquine resistant Plasmodium vivax malaria in India.
                 Tropical Medicine and International Health, 1996, 1:816–819.
            55.   Buchachart K et al. Effect of primaquine standard dose (15 mg/day for 14 days) in the
                 treatment of vivax malaria patients in Thailand. Southeast Asian Journal of Tropical
                 Medicine and Public Health, 2001, 32:720–726.
            56.  Phan GT et al. Artemisinin or chloroquine for blood stages Plasmodium vivax malaria in
                 Vietnam. Tropical Medicine and International Health, 2002, 7:858–864.
            57.   Gogtay NJ et al. Efficacies of 5- and 14-day primaquine regimens in the prevention of
                 relapse in Plasmodium vivax infections. Annals of Tropical Medicine and Parasitology, 1999,
                 93:809–812.
            58.  Alecrim MC, Alecrim W, Macedo V. Plasmodium vivax resistance to chloroquine (R2) and
                 mefloquine (R3) in Brazilian Amazon region. Revista da Sociedade Brasileira de Medicina
                 Tropical, 1999, 32:67–68.
            59.   Young MD, Burgens RW. Pyrimethamine resistance in Plasmodium vivax malaria. Bulletin
                 of the World Health Organization, 1959, 20:27–36.
            60.  Laing ABG. Hospital and field trials of sulformethoxine with pyrimethamine against
                 Malaysian strains of Plasmodium falciparum and P. vivax. Medical Journal of Malaysia,
                 1968, 23:5–19.




   184
   193   194   195   196   197   198   199   200   201   202   203